AstraZeneca PLC
AZN: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 52,871.00 | Fshy | Spmltpndj |
AstraZeneca's Strong Portfolio and Developing Pipeline Support Robust Long-Term Growth
Business Strategy and Outlook
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The replenishment of new drugs is offsetting the past patent losses on gastrointestinal drug Nexium and cholesterol reducer Crestor, and the company is well positioned for growth.